SOURCE-LINKED INTELLIGENCE
Developing a human-based stem cell model for reproductive toxicity
filing reproductive safety data to the regulatory authorities. This ReproTox assay will be further optimised (increase throughput, standardise measurements) and integrated with a software innovation (machine learning algorithm to automate quantification and webtool), before we carry out a pilot screen using FDA-approved spermatotoxic compounds and market research to define the commercialisation route. Reducing the number of compounds that show male reproductive toxicity at very early stages of drug development will contribute to an effective first-tier toxicity screening, not only providing standard protocols for quantitative, rapid, cost-effective, high-throughput, scalable and reproducible toxicity testing, but also reducing, perhaps eventually replacing animal use. ReproTox will ultimately lead to economic, societal, environmental, health and ethical benefits.
Read original source ↗ Open in workspace
- recordType
- award
- status
- SIGNED
- region
- EU
- value
- 150000
- unit
- EUR
Evidence & attribution
European Commission, CORDIS Horizon Europe project dataset. Metadata adapted.
License: CORDIS reuse policy
First collected: 2026-09-20T03:21:21.440Z. This is not the publication date.